Skip Navigation


Carcinogenesis Advance Access originally published online on July 14, 2008
Carcinogenesis 2008 29(9):1788-1793; doi:10.1093/carcin/bgn166
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/9/1788    most recent
bgn166v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ochs-Balcom, H. M.
Right arrow Articles by Li, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ochs-Balcom, H. M.
Right arrow Articles by Li, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Association of vitamin D receptor gene variants, adiposity and colon cancer

Heather M. Ochs-Balcom1,2, Mine S. Cicek3, Cheryl L. Thompson2,4,5, Thomas C. Tucker6, Robert C. Elston2,5, Sarah J.Plummer7,8, Graham Casey7,8 and Li Li2,4,5,*

1 Department of Social and Preventive Medicine, State University of New York at Buffalo, Buffalo, NY, USA
2 Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA
3 Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA
4 Department of Family Medicine, Case Western Reserve University/University Hospitals Case Medical Center, Cleveland, OH, USA
5 Case Center for Transdisciplinary Research on Energetics and Cancer, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA
6 Cancer Control Program, University of Kentucky, Lexington, KY, USA
7 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
8 Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA

* To whom correspondence should be addressed. Research Division, Department of Family Medicine, Case Western Reserve University, 11001 Cedar Avenue, Suite 306, Cleveland, OH 44106-7136, USA. Tel: +1 216 368 5437; Fax: +1 216 368 4348; Email: lxl62{at}cwru.edu


   Abstract
Top
 Abstract
Introduction
 Materials and methods
 Results
 Discussion
 Funding
 References
 
Vitamin D receptor (VDR) gene variants have been variably associated with risk of colon cancer in epidemiologic studies. We sought to further clarify the relationship between colon cancer and three single-nucleotide polymorphisms (SNPs) in the VDR gene (Cdx-2, FokI and TaqI) in a population-based case–control study of 250 incident cases and 246 controls. Colon cancer cases were more frequently homozygous for the Cdx-2 A allele (9.2 versus 4.1%, P = 0.06). Cdx-2 AA homozygotes were at increased risk with an unadjusted odds ratio (OR) of 2.47 [95% confidence interval (CI): 1.13–5.37, P = 0.022]; adjustment for age, sex, body mass index (BMI), non-steroidal anti-inflammatory use and family history of colorectal cancer yielded an OR of 2.27 (CI: 0.95–5.41, P = 0.065). Carriers of the FokI TT genotype were also at increased risk with an adjusted OR of 1.87 (CI: 1.03–3.38, P = 0.038). Haplotype analyses showed significant increased colon cancer risk for carriers of the Cdx-2–FokI A-T haplotype and the FokI-TaqI T-G haplotype. The three-SNP Cdx-2–FokI–TaqI (A-T-G) haplotype showed a similar association with an adjusted OR of 3.63 (CI: 1.01–13.07). A strong positive association was observed for the Cdx-2 variant among individuals with low BMI or low waist circumference. Our results suggest that genetic variation at the VDR locus, in particular Cdx-2 and FokI SNPs, may influence colon cancer risk and these associations may be modified by adiposity.

Abbreviations: BMI, body mass index; CI, confidence interval; HWE, Hardy–Weinberg equilibrium; LD, linkage disequilibrium; MAF, minor allele frequency; (25(OH)D), 25-hydroxyvitamin D; OR, odds ratio; PCR, polymerase chain reaction; SNP, single nucleotide polymorphism; VDR, vitamin D receptor


   Introduction
Top
 Abstract
 Introduction
Materials and methods
 Results
 Discussion
 Funding
 References
 
The observation of an ecologic correlation between solar radiation exposure and colon cancer risk (1,2) has spawned a number of epidemiologic studies of the associations of dietary vitamin D intake, serum levels of vitamin D metabolites and more recently vitamin D receptor (VDR) gene variants and colon cancer. While a non-significant inverse association of dietary vitamin D intake and colon cancer risk was found in a number of prospective studies (3,4), analyses of plasma 25-hydroxyvitamin D (25(OH)D) concentrations, a biomarker for vitamin D, generally support an inverse association (1,5–8). In animal models, the active form of vitamin D, 1,25-dihydroxyvitamin D3, reduces cellular proliferation and promotes differentiation (9–11), providing biological evidence for the involvement of vitamin D in carcinogenesis.

The VDR gene, located on chromosome 12, plays an important role in a number of different pathways including calcium absorption, bone metabolism, immune cell differentiation and proliferation, as well as cellular processes of carcinogenesis, including differentiation, proliferation and apoptosis (12–15). Underlying variability at the VDR gene locus may therefore influence proliferation of cancer cells and differentiation directly, and also influence the downstream action of the nuclear VDR complex acting as a transcription factor on vitamin D-responsive genes.

Several epidemiologic studies have examined the association of various VDR genetic variants and colon cancer, and the results are inconsistent (16–30). The first study to date that analyzed the VDR Cdx-2 single-nucleotide polymorphism (SNP) and colon cancer, which is functional and affects VDR transcription (31), reported increased risk for carriers of the Cdx-2-bearing haplotype, but no significant individual SNP association in 1574 cases and 1970 controls (29). Interestingly, the reported association for the Cdx-2-bearing haplotype was in the opposite hypothesized direction based on the functional effect of this SNP on VDR transcription. We sought to further clarify the association of the Cdx-2 SNP as well as two other VDR SNPs (FokI and TaqI) with colon cancer in a population-based incident case–control study. We also explored potential effect modification by body mass index (BMI) and waist circumference since obesity is related to decreased serum 25(OH)D levels (32,33) and increased risk of colon cancer (34,35).


   Materials and methods
Top
 Abstract
 Introduction
 Materials and methods
Results
 Discussion
 Funding
 References
 
Study population
The study design of this population-based case–control study has been described elsewhere (36). Briefly, eligible cases were identified through the population-based Surveillance, Epidemiology and End Results Kentucky Cancer Registry covering all residents living in the State of Kentucky at the time of diagnosis. We queried the cancer registry database every 3 months and identified all histopathologically confirmed incident primary colon cancer cases reported within 6 months of diagnosis preceding the recruitment. Cancers of the rectosigmoid were classified as colon cancer and included in the study, whereas rectal cancers were excluded.

We first sent an introductory letter explaining the study to potentially eligible cases. After 3 weeks or when subject initiated contact, we phoned each case subject for a screening interview to determine eligibility and their willingness to participate in the study. We collected information on demographics, family history of colorectal cancer and personal history of cancer at the recruitment phone call. We then used a two-step approach to collect blood samples and lifestyle questionnaire data. First, we sent a prepacked phlebotomy kit with detailed written instructions for blood sample collection and written consent forms to each case subject. Participants were instructed to go to their physician offices or adjacent medical facilities for blood draw after overnight fasting. The samples were collected in purple-top (K3EDTA) blood collection tubes and shipped overnight on frozen ice pack. Upon receipt, the blood tubes were spun for 15 min at 600g and aliquots of plasma and concentrated buffy coat were prepared and frozen at –80°C. We then sent each participant a self-administered lifestyle risk factor questionnaire developed by the National Cancer Institute Colon Cancer Familial Cancer Registry (http://epi.grants.cancer.gov/documents/CFR/center_questionnaires/Colon/LA/ColonRiskFactor_USC.pdf) to collect detailed information on family history of colorectal cancer, lifestyle and behavioral risk factors. Height, weight and waist and hip circumference were also collected via self-measurement.

We used random digital dialing to recruit population controls following a protocol similar to that described above for the cases. As a proxy for frequency match of the residential locations between the cases and the controls, the area codes and exchanges of the phone numbers of potential cases were used, along with randomly generated four digit numbers, to produce the list of phone numbers for control recruitment. Recruitment was not conducted when a business was reached. We originally recruited controls who were ≥30 years, but later changed the study protocol to recruit controls age ≥40 years, in efforts to recruit a control sample that was more similar in age to the study cases. Controls were free of personal history of cancer other than skin cancer. We excluded those with known inflammatory bowel diseases, family history of familial adenomatous polyposis and hereditary non-polyposis colorectal cancer.

As with case subjects, each control first donated a sample of blood after fasting overnight and then was asked to complete the self-administered risk factor questionnaire.

The participation rates were 72.2% for the cases and 62.5% for eligible controls. All participants provided written informed consent. The study was approved by the Institutional Review Boards of the University of Kentucky, Lexington and Case Western Reserve University/University Hospitals of Cleveland.

Genotyping
Genomic DNA was extracted from buffy coats/blood using the EZ1 DNA Blood kit (QIAGEN, Valencia, CA). All purified DNA samples were diluted to a constant DNA concentration of 5 ng/µl in 10 mM Tris and 5 mM ethylenediaminetetraacetic acid buffer (pH 8). Three VDR variants were examined as follows: the Cdx-2 SNP in the 5' promoter region of the VDR gene (rs11568820), the FokI polymorphism in exon 2 (rs10735810) and TaqI in exon 9 (rs731236).

Two of the VDR variants, FokI and TaqI, were detected by using the Amplifluor® SNPs HT Genotyping System (Chemicon International, Temecula, CA). Amplifluor® AssayArchitectTM software was used to design polymerase chain reaction (PCR) primers. The PCRs were performed in a 384-well format with the following primers: TaqI reverse primer 5'-TATCCCCGTGCCCACAGAT-3'; A allele forward specific primer 5'-GAAGGTGACCAAGTTCATGCTTCGGTCCTGGATGGCCTCAA-3'; G allele forward specific primer 5'-GAAGGTCGGAGTCAACGGATTCGGTCCTGGATGGCCTCG-3' and FokI reverse primer 5'-AAGTGCTGGCCGCCATT-3'; T allele forward specific primer 5'-GAAGGTGACCAAGTTCATGCTGCTTGCTGTTCTTACAGGGAT-3'; C allele forward specific primer 5'-GAAGGTCGGAGTCAACGGATTTGCTTGCTGTTCTTACAGGGAC-3'. PCRs were performed in a total reaction volume of 5 µl using TitaniumTM Taq polymerase (BD Clontech®, Mountain View, CA) and 5 ng of genomic DNA as recommended by the manufacturer, followed by an end-point read and genotype analysis using the ABI Prism 7900HT and SDS 2.1 software (Applied Biosystems, Foster City, CA).

Analysis of the Cdx-2 variant was performed by Custom TaqMan® SNP Genotyping assay (Applied Biosystems). PCRs were performed according to the manufacturer’s instructions in a 384-well format in a total reaction volume of 5 µl using 10 ng of genomic DNA and the following primer sequences; forward 5'-ACATCTTTTGTATCAGGAACTTATATATATTCCTGAGTA-3'; reverse 5'-CAGTATTTTTCAAAATTTTAACTGCAACCCAT-3'; FAM probe 5'-CTAGGTCACAATAAAA-3' and VIC probe 5'-AACTAGGTCACAGTAAAA-3'. An ABI Prism 7900HT instrument was used to perform plate reading. Automated allele calling was performed by allelic discrimination plots using the SDS version 2.1 software from Applied Biosystems.

The genotyping failure rate was <0.1%. Two percent replicate samples were sequenced for quality control and had a concordance rate of 100%. Laboratory personnel were blinded to case–control status.

Statistical analysis
The analyses presented here are based on a sample of 266 incident colon cancer cases and 267 cancer-free controls from an ongoing case–control study. We excluded a small number of participants of other self-reported ethnic groups (16 cases and 21 controls) to minimize the possibility of population stratification bias—spurious associations due to differences in genotype frequencies and disease incidences in individuals of different ancestries. All analyses herein include the Caucasian sample of 250 cases and 246 controls.

We examined differences in demographic and lifestyle risk factors using chi-square tests and Student’s t-tests. We estimated allele and genotype frequencies and assessed deviations from Hardy–Weinberg equilibrium (HWE) in cases and controls separately using chi-square tests with one degree of freedom. The difference in disequilibrium between cases and controls and the overall population disequilibrium assuming a disease prevalence ranging from 1 to 5% were also assessed using chi-square tests with one degree of freedom.

Calculation of the extent of linkage disequilibrium (LD) between SNPs was performed using Haploview (37). We computed genotype-specific odds ratios (ORs) using unconditional logistic regression models under additive, dominant and recessive genetic models for each of the three SNPs. We used individuals homozygous for the common allele as the referents for additive and dominant models. For the recessive model, we combined those with one or two copies of the common allele and used this as the reference category. We estimated the crude ORs and multivariate ORs adjusted for age, sex, non-steroidal anti-inflammatory drug use, BMI and family history of colorectal cancer. We dichotomized BMI and waist circumference based on the median values in control subjects (26.78 kg/m2 and 93.98 cm, respectively) when examining effect modification of the association of VDR genotype and colon cancer risk by adiposity. In addition, we examined effect modification by age and sex, judging a P-value <0.10 as evidence for statistical interaction. We used the Statistical Package for Social Sciences software unless otherwise noted (38).

We estimated haplotype frequencies of 2- and 3-SNP haplotypes using the expectation maximization algorithm within the UNPHASED software and estimated risk associated with each haplotype with the most common haplotype as the reference category using unconditional logistic regression (39,40).


   Results
Top
 Abstract
 Introduction
 Materials and methods
 Results
Discussion
 Funding
 References
 
Table I shows the descriptive characteristics of the study sample and allele frequencies of VDR. Cases were more likely to be older and male, with cases and controls ranging from 21 to 90 years and 29 to 87 years, respectively. Cases had higher BMI and waist circumference, but the differences were not statistically significant. There were no significant differences according to smoking status; however, we found a higher proportion of current smokers in controls. In our study population, there was no significant population deviation from HWE. The Cdx-2 allele frequency was consistent with HWE among the controls (P = 0.95), but was out of Hardy–Weinberg proportions in colon cancer cases (P = 0.03), with increased homozygosity. Allele distributions of FokI and TaqI were consistent with HWE for both cases and controls. Also, the estimated disequilibrium coefficients for cases and controls were in opposite directions for all the SNPs, with no significant deviation from HWE in the population as a whole assuming a disease prevalence between 1% (P = 0.57) and 5% (P = 0.17). Overall, we observed weak LD between TaqI and FokI and between FokI and Cdx-2, with D' values of 0.05 and 0.01, respectively. We observed moderate LD between the TaqI and Cdx-2 SNPs, with a D' estimate of 0.20 in the cases and 0.30 in the controls.


View this table:
[in this window]
[in a new window]

  		Table I. Kentucky colon cancer study demographics and allele frequencies

 
The results for the main effects of VDR genotype and risk of colon cancer are given in Table II. We observed increased risk for carriers of the Cdx-2 AA genotype in both the additive and recessive models. Adjustment for covariates slightly reduced the OR estimates to only borderline significance (P = 0.065 and 0.069, respectively). Carriers of homozygous FokI T allele were also at increased risk of colon cancer in both additive and recessive models. There was no statistically significant association for TaqI.


View this table:
[in this window]
[in a new window]

  		Table II. Association of VDR SNP genotypes and colon cancer risk

 
Table III shows the results for haplotype analyses. In the adjusted models, individuals carrying the Cdx-2–FokI A-T haplotype and the FokI-TaqI T-G haplotype were both at increased risk. Consistent with these results, those carrying a haplotype comprised of the three minor Cdx-2–FokI–TaqI alleles (A-T-G) had >3-fold increase of risk in covariate-adjusted models.


View this table:
[in this window]
[in a new window]

  		Table III. Association of VDR haplotypes and colon cancer riska

 
We found no evidence for effect modification of the association of VDR variants and colon cancer by age or sex. However, when we stratified the analyses by sex, we found a statistically significant association of FokI with colon cancer in men, with adjusted ORs and 95% confidence intervals (CIs) of 2.79 (1.03–7.58) and 2.03 (1.05–3.89) for recessive (TT) and dominant (CT or TT) models, respectively (data not shown). The minor allele frequency (MAF) for FokI in men was 0.44 and 0.36 in cases and controls, respectively, whereas for women the estimates were 0.40 for both cases and controls.

Table IV summarizes results from analyses stratified by BMI. We observed considerable differences in OR estimates for each of the three SNPs in stratified analyses, although tests for interactions were not statistically significant. Most notably, for Cdx-2 AA genotype, we found an >3-fold increase in risk for the low-BMI group (<26.8 kg/m2), and almost a 5-fold increase in risk for the low-waist circumference group (<94 cm) (OR = 5.04, 95% CI: 1.4–18.7) (data not shown), whereas the corresponding OR estimates were essentially at unity for those with higher BMI or waist circumference. In addition, for the high categories of BMI and waist circumference, individuals who carry two TaqI variant alleles were at increased risk in unadjusted models; however, these associations became non-significant in covariate-adjusted models. We observed a relatively high degree of correlation between BMI and waist circumference; Spearman correlation coefficients of 0.70 and 0.73 for cases and controls, respectively.


View this table:
[in this window]
[in a new window]

  		Table IV. Association of VDR SNPs genotypes and colon cancer risk according to BMI category

 
Approximately 61% of colon cancers were proximal and 39% were distal. When we analyzed whether VDR variants are more strongly associated with either proximal or distal tumors, we found stronger associations for proximal tumors (data not shown). The Cdx-2 AA genotype was associated with increased risk of proximal tumors, OR = 2.84, 95% CI: 1.21–6.68, but this association became non-significant when adjusted for covariates. For TaqI, there was also increased risk for the rare (GG) genotype, with significant crude and adjusted OR estimates of 1.98, 95% CI: 1.10–3.56 and 2.22, 95% CI: 1.17–4.23, respectively. There were no significant associations for distal cancers in our study.


   Discussion
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
Funding
 References
 
In this population-based case–control study, we found a statistically significant association between VDR Cdx-2 variant and colon cancer risk. Those carrying two copies of Cdx-2 A allele had a >2-fold increase of risk. We also found evidence for increased risks for the FokI variant (T allele) in recessive and additive models. Haplotype analyses further showed that the (Cdx-2–FokI–TaqI A-T-G) haplotype is associated with >3-fold increase of colon cancer risk. These results add evidence for a potential role of inherited VDR variants in the development of colon cancer.

The Cdx-2 SNP (G/A polymorphism), located in the promoter at the 5' end of the VDR gene, is a known binding site for the Cdx-2 intestinal-specific transcription factor (31,41). The Cdx-2 polymorphism is believed to be important in the regulation of calcium absorption; the G allele substitution eliminates the Cdx-2 transcription factor-binding site and therefore reduces VDR transcription (31). Since the Cdx-2 A allele is hypothesized to increase VDR transcription and consequently increased intestinal calcium absorption, we hypothesized that the A allele is protective for colon cancer. However, we found that the Cdx-2 AA (rare) genotype increases risk for colon cancer in our study. Our results are in line with a previous study by Slattery et al. (29) showing increased risk of colon cancer for carriers of a haplotype that includes the Cdx-2 A allele (n = 1574 cases, 1970 controls). The Cdx-2 MAFs in our control sample and that reported by Slattery et al. were very similar (0.19–0.20), whereas another recent study that found no significant association of Cdx-2 and colorectal cancer had a MAF of 0.34 in a Russian sample of controls (30). Flugge et al. (30) found no differences in the Cdx-2 MAF between cases and controls, which may partly explain the lack of significant association with colon cancer; however, these are different populations and these differences may influence the association of VDR and colon cancer.

There are four published studies that have investigated Cdx-2 and prostate cancer and the results are not in agreement (42–45). Two of these studies that measured ultraviolet exposure are conflicting, as carriers of the Cdx-2 A allele with high ultraviolet exposure at increased risk in one study (42) and reduced risk in the other (44). Two other studies found no significant association of Cdx-2 and prostate cancer risk (43,45). A recent study of squamous cell lung cancer with similar Cdx-2 allele frequencies reported enhanced survival for carriers of the GA or AA Cdx-2 genotypes (46), whereas two other studies of skin and ovarian cancer were non-significant for Cdx-2 (47,48).

A notable finding is the deviation of the Cdx-2 SNP from Hardy–Weinberg proportions in our case subjects, for an excess of the rare (A) allele. We examined whether age difference between the cases and controls could have explained this deviation, but found no such evidence for an influence by age (data not shown). A departure from Hardy–Weinberg proportions may be explained by population stratification, genotyping error, chance or a true association when the departure is observed with opposite sign in cases and controls. Since our sample is solely Caucasian and our genotype data are of high quality, we believe that population stratification and genotyping error are unlikely explanations. This is further supported by the fact that the other two SNPs examined were consistent with Hardy–Weinberg proportions in both cases and controls in our study population and that for all three SNPs there was no significant population deviation from HWE. The most probable explanation is that our observation represents a real association with Cdx-2 conferring increased risk for colon cancer in an additive or recessive manner or being in LD with an unknown causal variants (49–51).

The FokI SNP (C/T polymorphism) in exon 2 is also of particular interest, owing to its functional significance. The C allele (also referred to as the ‘F’ allele) results in a VDR protein that is shorter by three amino acids than the T allele (f) (49). The more active, shorter protein is thought to result in enhanced VDR transcription activity. Consistent with this functional study, our results show that the FokI T allele (the minor allele in Caucasians) is associated with increased risk of colon cancer. Others who have analyzed FokI genotype variants and risk of adenomas (239 cases and 228 controls) (23) and colon cancer (1174 cases and 1174 controls) (25) found no significant association. We did not find evidence for a statistical interaction of sex and FokI, but we did find a strong association of FokI and colon cancer in men in stratified analyses. Like adiposity, sex is related to serum (25(OH)D) levels, with women having lower concentrations than men (50). Further replication is needed, as well as future investigation regarding how these functional VDR variants correlate with VDR expression and how the variants are therefore related to circulating (25(OH)D) levels in men and women.

We observed a significantly increased risk for carriers of the Cdx-2–FokI A-T, the FokI–TaqI T-G and the Cdx-2–FokI–TaqI A-T-G haplotypes, which is consistent with the identified individual SNP genotypic risks. It is important to note that it is unlikely that the departure from Hardy–Weinberg proportions for Cdx-2 introduced bias during estimation of haplotype frequencies because the excess is toward homozygosity (51). Our haplotype results are not in agreement with those published by Sweeney et al. (27), where common haplotypes carrying the FokI common C allele (also referred to as F) were associated with increased colon cancer risk. These differences are not easily explained. The FokI allele frequencies in our study were exactly the same as reported by Sweeney et al. (27) and their study was much larger (1811 cases and 1451 controls). The authors used two different SNPs when constructing their haplotypes (FokI, BsmI and polyA repeat), whereas our haplotypes were constructed using Cdx-2, TaqI and FokI.

The TaqI SNP is located at the 3' end of the gene, and is reported to be in high LD with neighboring polymorphisms including BsmI and ApaI (52,53). Also nearby is the polyA repeat polymorphism, which is also in LD with the four aforementioned SNPs (24,52,54,55). In our study, we did not observe significant associations for the TaqI SNP in the overall analysis, but did so in analyses stratified by adiposity. Many studies have analyzed the association of TaqI and colon cancer, and also other variants in the 3' region including BsmI, ApaI and the polyA repeat. Slattery et al. (24) was the first group to report that purported low-risk genotypes that included 3' VDR variants were associated with decreased cancer risk in a study of 250 cases and 364 controls. The same group reported an interaction of low-risk VDR genotype (BsmI and polyA variants) with BMI (25), calcium and vitamin D intake (26).

Obese individuals may have lower levels of circulating 25(OH)D than non-obese individuals (56,57), possibly due to sequestration by adipose tissue (58), resulting in a vitamin D-deficient state; therefore, adiposity may modify the relation between VDR and colon cancer. Indeed, we found evidence for significant interactions of Cdx-2 and TaqI with BMI and waist circumference, with the highest colon cancer risk associated with Cdx-2 in the low-adiposity category and increased risk associated with TaqI in the high-adiposity category. It is important to note, however, that due to the limited power in our study, these analyses of interactions shall be considered as exploratory only.

In spite of the weak epidemiologic evidence for differences in proximal and distal colon cancers, there is some evidence that these sites are biologically different (59,60). In our study, we found evidence for stronger associations of VDR variants with proximal colon cancers, but this may be due to low power to detect associations in the distal group; therefore, further studies are necessary in larger samples.

Weaknesses of our study include potential information bias from the case–control study design and use of self-reported height, weight and waist circumference. However, correlations between self-reported and measured weight are generally quite high (61) and self-reported weight has been shown to be accurately recalled up to 28 years prior in elderly subjects (62). Although we performed several statistical tests, we did not adjust for multiple comparisons here when we stratified our analyses by adiposity because our intent was to generate hypotheses about potential effect modification by adiposity on the association of VDR genetic polymorphisms with colon cancer risk and inducing such statistical penalties would inhibit discovery (63). The relatively modest sample size also limited the statistical power to test for interaction; thus, we could not completely rule out the possibility of chance findings for the observed differential associations. Confirmation and replication of our results in larger studies are warranted.

In summary, in this population-based case–control study, we found that VDR gene variation, especially the Cdx-2 and FokI SNPs, may influence risk of colon cancer in Caucasians. More research is necessary to confirm these findings and functionally characterize the VDR variants. Also, the interaction of VDR variants with adiposity is an interesting avenue for further research.


   Funding
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Funding
References
 
Damon Runyon Cancer Research Foundation Clinical Investigator Award (CI-8) to L.L.; Case Center for Transdisciplinary Research on Energetics and Cancer (U54 CA-116867-01) to L.L.; National Cancer Institute K22 Award (K22 CA120545-01) to L.L.; Cancer Center Support Grant (P30CAD43703 to R.C.E., R25 CA094186 to H.M.O.-B.); U.S. Public Health Service Resource Grant (RR03655) from the National Center for Research Resources to program package S.A.G.E.


   Acknowledgments
 
The authors would like to thank Dr Amy Millen for her thoughtful comments on the manuscript. Some of the results of this paper were obtained by using the program package S.A.G.E.

Conflict of Interest Statement: None declared.


   References
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Funding
 References
 

  1. Garland CF, et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet (1989) 2:1176–1178.[Web of Science][Medline]
  2. Garland CF, et al. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int. J. Epidemiol. (1980) 9:227–231.[Abstract/Free Full Text]
  3. Giovannucci E. The epidemiology of vitamin D and colorectal cancer: recent findings. Curr. Opin. Gastroenterol. (2006) 22:24–29.[Web of Science][Medline]
  4. Martinez ME, et al. Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. Cancer Epidemiol. Biomarkers Prev. (1998) 7:163–168.[Abstract]
  5. Wu K, et al. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J. Natl Cancer Inst. (2007) 99:1120–1129.[Abstract/Free Full Text]
  6. Braun MM, et al. Colon cancer and serum vitamin D metabolite levels 10-17 years prior to diagnosis. Am. J. Epidemiol. (1995) 142:608–611.[Abstract/Free Full Text]
  7. Feskanich D, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol. Biomarkers Prev. (2004) 13:1502–1508.[Abstract/Free Full Text]
  8. Tangrea J, et al. Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes Control (1997) 8:615–625.[CrossRef][Web of Science][Medline]
  9. Sitrin MD, et al. Dietary calcium and vitamin D modulate 1,2-dimethylhydrazine-induced colonic carcinogenesis in the rat. Cancer Res. (1991) 51:5608–5613.[Abstract/Free Full Text]
  10. Tong WM, et al. Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression. Eur. J. Cancer (1998) 34:2119–2125.[CrossRef][Web of Science][Medline]
  11. Xue L, et al. Influence of dietary calcium and vitamin D on diet-induced epithelial cell hyperproliferation in mice. J. Natl Cancer Inst. (1999) 91:176–181.[Abstract/Free Full Text]
  12. Haussler MR, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. (1998) 13:325–349.[CrossRef][Web of Science][Medline]
  13. Uitterlinden AG, et al. Genetics and biology of vitamin D receptor polymorphisms. Gene (2004) 338:143–156.[CrossRef][Web of Science][Medline]
  14. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control (2005) 16:83–95.[CrossRef][Web of Science][Medline]
  15. Lamprecht SA, et al. Cellular mechanisms of calcium and vitamin D in the inhibition of colorectal carcinogenesis. Ann. N. Y. Acad. Sci. (2001) 952:73–87.[Web of Science][Medline]
  16. Boyapati SM, et al. Calcium, vitamin D, and risk for colorectal adenoma: dependency on vitamin D receptor BsmI polymorphism and nonsteroidal anti-inflammatory drug use? Cancer Epidemiol. Biomarkers Prev. (2003) 12:631–637.[Abstract/Free Full Text]
  17. de Jong MM, et al. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. (2002) 11:1332–1352.[Abstract/Free Full Text]
  18. Ingles SA, et al. Vitamin D receptor polymorphisms and risk of colorectal adenomas (United States). Cancer Causes Control (2001) 12:607–614.[CrossRef][Web of Science][Medline]
  19. Kim HS, et al. Vitamin D receptor polymorphism and the risk of colorectal adenomas: evidence of interaction with dietary vitamin D and calcium. Cancer Epidemiol. Biomarkers Prev. (2001) 10:869–874.[Abstract/Free Full Text]
  20. Murtaugh MA, et al. Vitamin D receptor gene polymorphisms, dietary promotion of insulin resistance, and colon and rectal cancer. Nutr. Cancer (2006) 55:35–43.[CrossRef][Web of Science][Medline]
  21. Park K, et al. Start codon polymorphisms in the vitamin D receptor and colorectal cancer risk. Cancer Lett. (2006) 237:199–206.[CrossRef][Web of Science][Medline]
  22. Peters U, et al. Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. Cancer Epidemiol. Biomarkers Prev. (2004) 13:546–552.[Abstract/Free Full Text]
  23. Peters U, et al. Vitamin D, calcium, and vitamin D receptor polymorphism in colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. (2001) 10:1267–1274.[Abstract/Free Full Text]
  24. Slattery M, et al. Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control (2001) 12:359–364.[CrossRef][Web of Science][Medline]
  25. Slattery ML, et al. Associations between BMI, energy intake, energy expenditure, VDR genotype and colon and rectal cancers (United States). Cancer Causes Control (2004) 15:863–872.[CrossRef][Web of Science][Medline]
  26. Slattery ML, et al. Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. Int. J. Cancer (2004) 111:750–756.[CrossRef][Web of Science][Medline]
  27. Sweeney C, et al. Haplotype analysis of common vitamin D receptor variants and colon and rectal cancers. Cancer Epidemiol. Biomarkers Prev. (2006) 15:744–749.[Abstract/Free Full Text]
  28. Wong HL, et al. Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese. Carcinogenesis (2003) 24:1091–1095.[Abstract/Free Full Text]
  29. Slattery ML, et al. CDX2 VDR polymorphism and colorectal cancer. Cancer Epidemiol. Biomarkers Prev. (2007) 16:2752–2755.[Abstract/Free Full Text]
  30. Flugge J, et al. Vitamin D receptor haplotypes protect against development of colorectal cancer. Eur. J. Clin. Pharmacol. (2007) 63:997–1005.[CrossRef][Web of Science][Medline]
  31. Arai H, et al. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J. Bone Miner. Res. (2001) 16:1256–1264.[CrossRef][Web of Science][Medline]
  32. Parikh SJ, et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J. Clin. Endocrinol. Metab. (2004) 89:1196–1199.[Abstract/Free Full Text]
  33. Snijder MB, et al. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J. Clin. Endocrinol. Metab. (2005) 90:4119–4123.[Abstract/Free Full Text]
  34. Larsson SC, et al. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am. J. Clin. Nutr. (2007) 86:556–565.[Abstract/Free Full Text]
  35. Nock NL, et al. Associations between obesity and changes in adult BMI over time and colon cancer risk. Obesity (Silver Spring) (2008) 16:1099–1104.[Medline]
  36. Li L, et al. Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. Clin. Cancer Res. (2008) 14:633–637.[Abstract/Free Full Text]
  37. Barrett JC, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (2005) 21:263–265.[Abstract/Free Full Text]
  38. SPSS for Windows, Release 15.0.1.1 (2007) Chicago, IL: SPSS, Inc.
  39. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. (2003) 25:115–121.[CrossRef][Web of Science][Medline]
  40. Dudbridge F. UNPHASED User Guide (2006) Cambridge, UK: M.B.U. Technical Report 2006/5.
  41. Yamamoto H, et al. The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine. J. Bone Miner. Res. (1999) 14:240–247.[CrossRef][Web of Science][Medline]
  42. Bodiwala D, et al. Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. Environ. Mol. Mutagen. (2004) 43:121–127.[CrossRef][Web of Science][Medline]
  43. Cicek MS, et al. Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. (2006) 15:2549–2552.[Abstract/Free Full Text]
  44. John EM, et al. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res. (2005) 65:5470–5479.[Abstract/Free Full Text]
  45. Mikhak B, et al. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate (2007) 67:911–923.[CrossRef][Web of Science][Medline]
  46. Zhou W, et al. Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol. Biomarkers Prev. (2006) 15:2239–2245.[Abstract/Free Full Text]
  47. Han J, et al. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis (2007) 28:390–397.[Abstract/Free Full Text]
  48. Lurie G, et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol. Biomarkers Prev. (2007) 16:2566–2571.[Abstract/Free Full Text]
  49. Arai H, et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J. Bone Miner. Res. (1997) 12:915–921.[CrossRef][Web of Science][Medline]
  50. Black PN, et al. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. Chest (2005) 128:3792–3798.[CrossRef][Web of Science][Medline]
  51. Fallin D, et al. Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am. J. Hum. Genet. (2000) 67:947–959.[CrossRef][Web of Science][Medline]
  52. Morrison NA, et al. Prediction of bone density from vitamin D receptor alleles. Nature (1994) 367:284–287.[CrossRef][Web of Science][Medline]
  53. Morrison NA, et al. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. Proc. Natl Acad. Sci. USA (1992) 89:6665–6669.[Abstract/Free Full Text]
  54. Ingles SA, et al. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol. Biomarkers Prev. (1997) 6:93–98.[Abstract]
  55. Uitterlinden AG, et al. A large-scale population-based study of the association of vitamin D receptor gene polymorphisms with bone mineral density. J. Bone Miner. Res. (1996) 11:1241–1248.[Web of Science][Medline]
  56. Wortsman J, et al. Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. (2000) 72:690–693.[Abstract/Free Full Text]
  57. Liel Y, et al. Low circulating vitamin D in obesity. Calcif. Tissue Int. (1988) 43:199–201.[Web of Science][Medline]
  58. Mawer EB, et al. The distribution and storage of vitamin D and its metabolites in human tissues. Clin. Sci. (1972) 43:413–431.[Web of Science][Medline]
  59. Gervaz P, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis. Colon Rectum (2001) 44:364–372. discussion 372–373.[CrossRef][Web of Science][Medline]
  60. Iacopetta B. Are there two sides to colorectal cancer? Int. J. Cancer (2002) 101:403–408.[CrossRef][Web of Science][Medline]
  61. Willett WC. Nutritional Epidemiology (1998) New York, NY: Oxford University Press.
  62. Stevens J, et al. Accuracy of current, 4-year, and 28-year self-reported body weight in an elderly population. Am. J. Epidemiol. (1990) 132:1156–1163.[Abstract/Free Full Text]
  63. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology (1990) 1:43–46.[Medline]
Received March 27, 2008; revised July 8, 2008; accepted July 9, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. N. Poynter, E. T. Jacobs, J. C. Figueiredo, W. H. Lee, D. V. Conti, P. T. Campbell, A. J. Levine, P. Limburg, L. Le Marchand, M. Cotterchio, et al.
Genetic Variation in the Vitamin D Receptor (VDR) and the Vitamin D-Binding Protein (GC) and Risk for Colorectal Cancer: Results from the Colon Cancer Family Registry
Cancer Epidemiol. Biomarkers Prev., February 1, 2010; 19(2): 525 - 536.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. Jenab, J. McKay, H. B. Bueno-de-Mesquita, F. J.B. van Duijnhoven, P. Ferrari, N. Slimani, E. H.J.M. Jansen, T. Pischon, S. Rinaldi, A. Tjonneland, et al.
Vitamin D Receptor and Calcium Sensing Receptor Polymorphisms and the Risk of Colorectal Cancer in European Populations
Cancer Epidemiol. Biomarkers Prev., September 1, 2009; 18(9): 2485 - 2491.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Raimondi, H. Johansson, P. Maisonneuve, and S. Gandini
Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk
Carcinogenesis, July 1, 2009; 30(7): 1170 - 1180.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/9/1788    most recent
bgn166v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ochs-Balcom, H. M.
Right arrow Articles by Li, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ochs-Balcom, H. M.
Right arrow Articles by Li, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?